Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares traded down 7.5% during trading on Wednesday . The stock traded as low as $3.30 and last traded at $3.33, 1,430,499 shares traded hands during trading. An increase of 10% from the average session volume of 1,303,572 shares. The stock had previously closed at $3.60.

Several research analysts have recently commented on the company. Citigroup lowered their price target on Lexicon Pharmaceuticals from $15.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, July 30th. Stifel Nicolaus lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price target for the stock from $10.00 to $4.00 in a research report on Monday, July 29th. Gabelli upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Wednesday, September 11th. ValuEngine upgraded Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, BidaskClub upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, September 25th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. Lexicon Pharmaceuticals has an average rating of “Hold” and an average price target of $6.70.

The firm has a market capitalization of $382.58 million, a price-to-earnings ratio of -2.92 and a beta of 0.91. The firm has a 50 day moving average price of $2.39 and a 200-day moving average price of $4.55.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.13). The firm had revenue of $9.68 million during the quarter, compared to analyst estimates of $28.52 million. The company’s quarterly revenue was down 29.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.33) EPS. As a group, equities research analysts expect that Lexicon Pharmaceuticals, Inc. will post 0.69 EPS for the current year.

In related news, Director Christopher J. Sobecki acquired 25,000 shares of Lexicon Pharmaceuticals stock in a transaction dated Monday, September 16th. The shares were acquired at an average cost of $2.55 per share, for a total transaction of $63,750.00. Following the completion of the purchase, the director now owns 112,493 shares in the company, valued at $286,857.15. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Sam L. Barker acquired 24,000 shares of Lexicon Pharmaceuticals stock in a transaction dated Friday, August 2nd. The stock was bought at an average price of $1.18 per share, for a total transaction of $28,320.00. Following the completion of the purchase, the director now owns 40,187 shares of the company’s stock, valued at approximately $47,420.66. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 289,749 shares of company stock worth $618,230. Insiders own 6.40% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in LXRX. Vanguard Group Inc. raised its stake in shares of Lexicon Pharmaceuticals by 8.1% in the second quarter. Vanguard Group Inc. now owns 4,240,111 shares of the biopharmaceutical company’s stock valued at $26,670,000 after acquiring an additional 319,382 shares in the last quarter. First Manhattan Co. raised its stake in Lexicon Pharmaceuticals by 7.3% in the second quarter. First Manhattan Co. now owns 2,949,979 shares of the biopharmaceutical company’s stock valued at $18,555,000 after buying an additional 201,393 shares in the last quarter. Virtus ETF Advisers LLC acquired a new stake in Lexicon Pharmaceuticals in the second quarter valued at $901,000. Morgan Stanley raised its stake in Lexicon Pharmaceuticals by 158.0% in the second quarter. Morgan Stanley now owns 195,307 shares of the biopharmaceutical company’s stock valued at $1,229,000 after buying an additional 119,611 shares in the last quarter. Finally, Pictet Asset Management Ltd. raised its stake in Lexicon Pharmaceuticals by 13.4% in the second quarter. Pictet Asset Management Ltd. now owns 665,776 shares of the biopharmaceutical company’s stock valued at $4,188,000 after buying an additional 78,926 shares in the last quarter. Institutional investors and hedge funds own 98.87% of the company’s stock.

About Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Recommended Story: Stock Symbol

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.